Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.
Boasting 20+ speakers, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery, R&D and clinical development, this event is a unique opportunity for your team to identify and target the undruggable, elevate drug design for improved target selectivity, overcome the blood brain barrier and rationalize combinations for more durable responses.
Collaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity, maximal durability to deliver the best clinical outcomes.
To know more visit: https://kinase-inhibitors-summit.com/